Shire touts plan to extend dominance in ADHD market through 2029

This morning, drug giant Shire said a long-acting drug in development for attention-deficit hyperactivity disorder that could help the company fend off competition from generics until 2029 could launch in a little over two years, based on feedback from the Food and Drug Administration. Shire (Nasdaq: SHPG), whose U.S. headquarters are in Lexington, has been developing the ADHD drug known as SHP465 for years using the same active ingredient as its former best-selling drug, Adderall XR. It first filed…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news